IASO Bio's CAR-T Therapy Gains Approval for Clinical Trials in Japan IASO Biotherapeutics has received Clinical Trial Notification approval for their BCMA CAR-T cell therapy in Japan, marking a significant step in their global strategy.

IASO Bio's CAR-T Therapy Gains Approval for Clinical Trials in Japan #Japan #Tokyo #CAR-T_therapy #IASO_Biotherapeutics #BCMA_CAR-T

Revolutionary Findings on IASO Bio's CAR-T Therapy for Multiple Sclerosis Unveiled Recent research by IASO Biotherapeutics reveals groundbreaking results on their CAR-T therapy for treating Multiple Sclerosis, showcasing safety and efficacy.

Revolutionary Findings on IASO Bio's CAR-T Therapy for Multiple Sclerosis Unveiled #China #Shanghai #IASO_Biotherapeutics #Equecabtagene_Autoleucel #BCMA_CAR-T

IASO Bio Secures Significant Orphan Drug Designation for Novel CAR-T Therapy in South Korea IASO Biotherapeutics receives Orphan Drug Designation for Equecabtagene Autoleucel from South Korea, paving the way for innovative treatments in multiple myeloma.

IASO Bio Secures Significant Orphan Drug Designation for Novel CAR-T Therapy in South Korea #South_Korea #Seoul #CAR-T_therapy #IASO_Biotherapeutics #Equecabtagene_Autoleucel

IASO Bio's Equecabtagene Autoleucel Granted Orphan Drug Status by Saudi Authorities IASO Biotherapeutics' Equecabtagene Autoleucel earns Orphan Drug Designation from Saudi Food and Drug Authority to treat multiple myeloma.

IASO Bio's Equecabtagene Autoleucel Granted Orphan Drug Status by Saudi Authorities #China #Shanghai #Equecabtagene #Orphan_Drug #IASO_Biotherapeutics